

Contents

Session I

Expectations for Process Validation 1

Moderators: *G. Murano* (Genentech, USA)
B. Hughes (Wyeth Biopharma, USA)

Canadian Perspectives on Expectations for Process Validation 3

A. Ridgway

Expectations for Process Validation: Industry Perspectives 9

R. Francis

Session II

Strategies: Evolution of Validation Through the Product Life Cycle 15

Moderators: *G. Roessling* (Schering, Germany)
J. Purves (European Medicines Evaluation Agency, UK)

Statistical Tools for Setting In-Process Acceptance Criteria 17

R.J. Seely, L. Muryakazi, J. Haury

Experience with Validation of Clinical Trial Materials: An Inspector's Viewpoint 27

L. Wolfe

Session III

Upstream Processes 35

Moderators: *A. Lubiniecki* (GlaxoSmithKline, USA)
C. Joneckis (CBER/FDA, USA)

Validation of Fermentation Processes 37

A.S. Lubiniecki, A.R. Gardner, T.M. Smith, W.K. Wang, P.R. McAllister, M.M. Federici

Concurrent Breakout Sessions I

Strategies: Evolution of Validation Through the Product Life Cycle 45

Moderator: *B. Hughes* (Wyeth Biopharma, USA)

Site Transfer and Process Validation in Case of Herceptin API 47

W. Kuhne

Post-Approval Changes: Case Study	51
Moderators: <i>M. Malarkey</i> (CBER, FDA, USA) <i>B. Casey</i> (ThromboGenics, Ireland)	
Detection and Consequences of Recombinant Protein Isoforms: Implications for Biological Potency	53
<i>M.M. Federici, K. Venkat, N. Bam, K. Patel, P.R. Dal Monte, B. Fernie, P. Hensley, S. Carr, J. Baldoni, A. Truneh, J. Erickson</i>	
 <i>Session IV</i>	
Physical Methods of Separation	59
Moderators: <i>N. Henschel</i> (Boehringer Ingelheim Pharma, Germany) <i>A. Ridgway</i> (Bureau of Biologics, Health Canada)	
Current Issues in Validation of Chromatography	61
<i>G. Sofer</i>	
Validation of Sterilizing Grade Filtration	65
<i>M.W. Jornitz, T.H. Meltzer</i>	
 <i>Session V</i>	
Viral Clearance	71
Moderators: <i>G. Vicari</i> (Italy) <i>E. Bucci</i> (Kedrion, Italy)	
Viruses and Assuring Viral Safety	73
<i>J.S. Robertson</i>	
 <i>Concurrent Breakout Sessions II</i>	
Viral Clearance and Inactivation	79
Moderator: <i>H. Willkommen</i> (Paul-Ehrlich-Institut, Germany)	
Manufacturing Process for Antithrombin III Concentrate: Viral Validation Studies and Effects of Column Re-Use on Viral Safety	81
<i>A. Falbo</i>	
An Overview of Quantitative PCR Assays for Biologicals: Quality and Safety Evaluation	89
<i>Y. Xu, K. Brorson</i>	
Re-Processing	99
Moderators: <i>V. Anicetti</i> (Genentech, USA) <i>R. Franceschini</i> (Kedrion, Italy)	
Re-Processing Strategies for Biologicals API Manufacturing Processes	101
<i>U. Opitz</i>	
Re-Processing of Biological Products: Regulatory Considerations from the CBER Perspective	105
<i>E. Shacter</i>	
Summary of Concurrent Sessions	109
Closing Remarks	117